RECITALSPatent and Technology License Agreement • January 21st, 2009 • Cancer Detection Corp. • Services-commercial physical & biological research
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 24th, 2022 • Moleculin Biotech, Inc. • Pharmaceutical preparations • Texas
This AGREEMENT (“AGREEMENT”) is made by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“MD ANDERSON”), a member institution of SYSTEM, and MOLECULIN BIOTECH, INC. a Delaware corporation having a principal place of business located at 5300 Memorial Drive - Suite 950, Houston, Texas 77007 (“LICENSEE”).
ContractPatent and Technology License Agreement • May 5th, 2020 • Texas
EX-10.20 6 ex10-20.htm EXHIBIT 10.20 Exhibit 10.20 PATENT AND TECHNOLOGY LICENSE AGREEMENT THIS AGREEMENT is made as of this 31st day of December, 2012 (the “Effective Date”), by and between VERIFYME, INC., a Texas corporation (“LICENSOR”) and LASERLOCK TECHNOLOGIES, INC., a Nevada corporation (“LICENSEE”) (collectively the “Parties”). W I T N E S S E T H: WHEREAS, LICENSOR is the sole and exclusive owner of certain technology relating to local, mobile and cloud-based biometric security systems and methods of providing same identified more fully in the attached Schedule A (collectively, the “Technology”) and has the right to license certain United States Letters Patents and applications therefor identified more fully in the attached Schedule A (collectively, the “Patents”); and WHEREAS, LICENSEE desires to acquire an exclusive license under the Technology and under the Patents, for at least an initial period, and thereafter a non-exclusive license thereunder, for use in the development
POINTSOURCE TECHNOLOGIES, LLC AND JMAR TECHNOLOGIES, INC.Patent and Technology License Agreement • March 31st, 2005 • Jmar Technologies Inc • Measuring & controlling devices, nec • California
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L2664-MAIA BIOTECHNOLOGYPatent and Technology License Agreement • April 11th, 2022 • MAIA Biotechnology, Inc. • Pharmaceutical preparations • Texas
This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and MAIA Biotechnology, Inc., a Delaware corporation, with its principal place of business at 444 West Lake Street, Suite 1700, Chicago, IL 60606 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
PATENT AND TECHNOLOGY LICENSE AGREEMENT (CCz & DCW Technology)Patent and Technology License Agreement • June 2nd, 2014 • SunEdison Semiconductor LTD • Semiconductors & related devices • New York
This Patent and Technology License Agreement (“Agreement”), made and entered into as of May 27, 2014 and effective as of the Effective Date, is by and between SunEdison, Inc., a Delaware corporation (“SunEdison”), and SunEdison Semiconductor Limited, a company organized and existing under the laws of Singapore and having its registered office at 80 Robinson Road, #02-00, Singapore 068898 (“SSL”).
AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • November 24th, 2014 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • Washington
This AMENDED AND RESTATED PATENT AND TECHNOLOGY LICENSE AGREEMENT (“AGREEMENT”) is made on this 2nd day of January, 2012, by and between FRED HUTCHINSON CANCER RESEARCH CENTER (“FHCRC”), a Washington state nonprofit organization, with principal offices located at 1100 Fairview Ave. N., Seattle, Washington 98109, and ZetaRx BioSciences Inc., a Delaware corporation, having a principal place of business located at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“LICENSEE”).
ContractPatent and Technology License Agreement • May 5th, 2020 • Texas
EX-10.1 3 b86941exv10w1.htm EX-10.1 Exhibit 10.1 Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. PATENT AND TECHNOLOGY LICENSE AGREEMENT This thirty-nine (39) page AGREEMENT (“AGREEMENT”) is made on this 11th day of September, 2006, by and between: (1) THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM; (2) THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (“HJF”), a Maryland tax-exempt corporation, whose address is 1401 Rockville Pike, Suite 600, Rockville Maryland 20852, on its own behalf and on behalf of THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (“USU”), an institution of higher learning within the Depar
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 30th, 2018 • Soliton, Inc. • Surgical & medical instruments & apparatus • Texas
This AGREEMENT (“AGREEMENT”) is made on this 5th day of April, 2012, by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of SYSTEM, and SOLITON, INC. a Delaware corporation having a principal place of business located at 1225 N. Loop West, Suite 725, Houston, Texas 77008 (“LICENSEE”).
AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations • Texas
This is AMENDMENT NO. 1 effective this 1st day of September, 1996, (“EFFECTIVE AMENDMENT NO. 1 DATE”) to the Patent and Technology License Agreement dated July 20, 1994 (hereinafter referred to as the “AGREEMENT”), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and INTROGEN THERAPEUTICS, INC,. located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • May 12th, 2023 • Citius Pharmaceuticals, Inc. • Pharmaceutical preparations
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • April 2nd, 2007 • Quick Med Technologies Inc • Surgical & medical instruments & apparatus • Florida
This Patent and Technology License Agreement (“Agreement”), effective this 23 day of March 2007 (the “Effective Date”), is by and between Quick-Med Technologies, Inc., a Delaware corporation having offices at 3427 SW 42nd Way, Gainesville, Florida 32608 (“QMT”) and Derma Sciences, Inc., a Pennsylvania corporation having offices at 214 Carnegie Center, Suite 100, Princeton, New Jersey 08540 (“DERMA”) (each singularly a “Party” and collectively the “Parties”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations • Texas
THIS AGREEMENT (“AGREEMENT”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“MDA”), a component institution of the SYSTEM and INTRON THERAPEUTICS, INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (“LICENSEE”).
EX-10.4 5 dex104.htm PATENT AND TECHNOLOGY LICENSE AGREEMENT CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND...Patent and Technology License Agreement • May 5th, 2020 • Texas
This AGREEMENT (“AGREEMENT”) is made on this 14th day of December, 2010, by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of SYSTEM, and ARROWHEAD RESEARCH CORPORATION a Delaware corporation having a principal place of business located at 201 South Lake Avenue, Suite 703, Pasadena, CA 91101 (“LICENSEE”).
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L3648-MAIA BIOTECHNOLOGYPatent and Technology License Agreement • April 11th, 2022 • MAIA Biotechnology, Inc. • Pharmaceutical preparations • Texas
This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and MAIA Biotechnology, Inc., a Delaware corporation, with its principal place of business at 444 West Lake Street, Suite 1700, Chicago, IL 60606 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 30th, 2020 • California
This Patent and Technology License Agreement (the “Agreement”) is made effective as of December , 2018 (the “Effective Date”) by and between Cell Science LTD., a corporation organized under the laws of the Republic of Cyprus with its principal place of business at 25 Berengaria, 25 Spyrou Araouzou, 4th floor, 3036 Limassol Cyprus (“Licensor”), and Bakhu Holdings, Corp., a Nevada corporation with its principal place of business at 387 Corona St., Suite 555, Denver, CO 80218 (“Licensee”) (collectively, the “Parties”, or individually, a “Party”).
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 2 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations • Texas
This is AMENDMENT NO. 2 effective this 8 day of August, 1997, (“EFFECTIVE AMENDMENT NO. 2 DATE”) to the Patent and Technology License Agreement dated July 20, 1994, as amended by that certain Amendment No. 1 effective September 1, 1996 (HEREINAFTER REFERRED TO AS THE “FIRST AMENDED AGREEMENT), by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (hereinafter referred to as “MDA”), located at Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (hereinafter referred to as “SYSTEM”) which is governed by a BOARD OF REGENTS (hereinafter referred to as “BOARD”) and INTROGEN THERAPEUTICS, INC., located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (hereinafter referred to as “LICENSEE”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • June 28th, 2012 • Quick-Med Technologies Inc • Surgical & medical instruments & apparatus • Florida
This Patent and Technology License Agreement (“Agreement”), effective this 1st day of October 2011 (the “Effective Date”), is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW Fourth Street, Gainesville, Florida 32601 (“QMT”) and Biosara Corporation., a Delaware corporation having offices at 103 Costa Bella Cove, Austin, Texas 78734 (“BIOSARA”) (each singularly a “Party” and collectively the “Parties”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 13th, 2012 • Derma Sciences, Inc. • Surgical & medical instruments & apparatus • Delaware
This Patent and Technology License Agreement (“Agreement”), effective as of the 12th day of July, 2012 (the “Effective Date”), is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW 4 Street, Gainesville, Florida 32601 (“QMT”) and Derma Sciences, Inc., a Pennsylvania corporation having offices at 214 Carnegie Center, Suite 300, Princeton, New Jersey 08540 (“DERMA”) (each singularly a “Party” and collectively the “Parties”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • July 15th, 2009 • Texas
This ____ (___) page AGREEMENT ("AGREEMENT") is made on this day of ________, 200__ between the BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("MDA"), a component institution of SYSTEM and __________________________, a _______________________ corporation having a principal place of business located at ____________________________ ("LICENSEE").
RECITALSPatent and Technology License Agreement • November 14th, 2003 • Us Global Aerospace Inc • Miscellaneous fabricated textile products • Massachusetts
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • February 21st, 2012 • Global Mobiletech, Inc. • Services-advertising • New York
THIS PATENT AND TECHNOLOGY LICENSE AGREEMENT is made as of December 15, 2011 (the “Effective Date”) between Soon Hock Lim, an individual, located at Unit M, Suite 807 Allway Gardens, Tsuen Wan, NT Hong Kong (“SHL”) and Global MobileTech, Inc., a Nevada corporation, with a business address at 1312 North Monroe, Suite 750, Spokane WA 99201 ("GMT"). Either SHL or GMT may hereinafter be individually referred to as a “Party” or collectively as the “Parties.” The Parties include any affiliate of a party.
PATENT AND TECHNOLOGY LICENSE AGREEMENT (as Amended)Patent and Technology License Agreement • August 9th, 2007 • Hana Biosciences Inc • Pharmaceutical preparations • Texas
THIS AGREEMENT ("AGREEMENT") is made on this 14th day of February, 2000 between the BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("MDA"), a component Institution of SYSTEM and INEX Pharmaceuticals Corp, a British Columbia corporation having a principal place of business located at 100 - 8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, BC, Canada V5J 5J8 ("LICENSEE").
FIRST AMENDMENT Patent and Technology License Agreement and Trademark Assignment Between IGL Pharma, Inc. and QSAM Therapeutics Inc.Patent and Technology License Agreement • November 30th, 2021 • QSAM Biosciences, Inc. • Specialty cleaning, polishing and sanitation preparations
This Patent and Technology License Agreement and Trademark Assignment Amendment (the “Amendment”) is made and entered into as of November 17, 2021 (the “Effective Date”), by and between IGL Pharma, Inc., a Delaware corporation, (“IGL Pharma”) having its principal place of business at 1004 S. Velasco Street, Angleton, Texas 77515 and QSAM Therapeutics Inc., (“QSAM”) a Texas corporation having its principal place of business 3616 Far West Blvd, Suite 117-292, Austin, Texas 78731. IGL Pharma and QSAM are each referred to herein as a “Party” and collectively as the “Parties.”
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 15th, 2006 • APA Enterprises, Inc. • Optical instruments & lenses • California
This Patent and Technology License Agreement ("License Agreement") is entered into and effective as of the 9th day of March, 2006 (the "Effective Date"), by and between INTERNATIONAL RECTIFIER CORPORATION, a company organized under the laws of the State of Delaware ("IR"), and APA Enterprises, Inc., a company organized under the laws of the State of Minnesota ("APA"). IR and APA each may be referred to herein as a "Party" and collectively as the "Parties."
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • July 30th, 2010 • Quick-Med Technologies Inc • Surgical & medical instruments & apparatus • Florida
This Patent and Technology License Agreement (“Agreement”), effective this 26th day of July 2010 (the “Effective Date”), is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW Fourth Street, Gainesville, Florida 32601 (“QMT”) and Viridis BioPharma Pvt. Ltd., an India corporation having offices at 6/10, Jogani Industrial Complex, V.N. Purav Marg, Chunabhatti, Mumbai – 400022, India (“VIRIDIS”) (each singularly a “Party” and collectively the “Parties”).
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • December 19th, 2023
NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the parties hereto agree as follows:
AMENDMENT # 2 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT BETWEEN SOON HOCK LIM AND GLOBAL MOBILETECH, INC.Patent and Technology License Agreement • October 24th, 2012 • Global Mobiletech, Inc. • Services-advertising
This Agreement to that certain Amendment #1 dated March 23, 2012 (“Amendment #1”) to the Patent and Technology License Agreement dated December 15, 2011 (the “License Agreement”), is made this 1st day of June, 2012.
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 8th, 2007 • Introgen Therapeutics Inc • Pharmaceutical preparations • Texas
This thirty-one (31) page AGREEMENT (“AGREEMENT”) is made on this 30th day of September, 2006, by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM, and Introgen Therapeutics, Inc., a Texas corporation having a principal place of business located at 301 Congress, Suite 1850, Austin, Texas 78701 (“LICENSEE”).
AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • March 22nd, 2016 • Moleculin Biotech, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 effective this 19th day of October, 2015 (“AMENDMENT NO. 1 EFFECTIVE DATE”), to the Patent and Technology License Agreement between the Parties dated June 21, 2010 (“ORIGINAL LICENSE”), is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (hereinafter “UTMDACC”), a member institution of SYSTEM, and MOLECULIN, LLC, a limited liability company organized and existing under the laws of the state of Texas, having a principal place of business located at 1973 West Clay, Houston, Texas 77019 (“LICENSEE”). BOARD and LICENSEE may be referred to hereafter collectively as the “PARTIES.”
AMENDMENT NO. 5 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT DATED JULY 31, 1994Patent and Technology License Agreement • March 8th, 2007 • Introgen Therapeutics Inc • Pharmaceutical preparations
This is AMENDMENT NO. 5 effective this 13th day of NOVEMBER December, 2006, to the Patent and Technology License Agreement dated July 20, 1994 (as amended, the AGREEMENT) is between THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (BOARD), an agency of the State of Texas, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (MDA), located at 1515 Holcombe Boulevard, Houston, Texas 77030, and INTROGEN THERAPEUTICS, INC., a Texas corporation, located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (LICENSEE).
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L2664-MAIA BIOTECHNOLOGYPatent and Technology License Agreement • May 31st, 2022 • MAIA Biotechnology, Inc. • Pharmaceutical preparations • Texas
This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and MAIA Biotechnology, Inc., a Delaware corporation, with its principal place of business at 444 West Lake Street, Suite 1700, Chicago, IL 60606 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
AMENDMENT NO. 4 TO PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 11th, 2021 • Moleculin Biotech, Inc. • Pharmaceutical preparations
This Amendment No. 4, effective as of the date fully executed by both Parties (“Amendment No. 4 Effective Date”), to that certain Patent and Technology License Agreement between the Parties dated April 2, 2012, as previously amended by Amendment No.1 dated October 19, 2015 and Amendment No. 2 dated November 1, 2018, and Amendment No. 3 dated May 20, 2020 (as so amended, the “Original License”), is made by and between the Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (hereinafter “UTMDACC”), a member institution of System, and Moleculin Biotech, Inc. (hereinafter “Licensee”), a Delaware corporation having a principal place of business located at 5300 Memorial Dr., Suite 950, Houston, Texas 77007. Board, on behalf of UTMDACC, and Licensee may herein be referred to collectively as the “Parties.”
PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • July 6th, 2018 • Soliton, Inc. • Surgical & medical instruments & apparatus • Texas
This AGREEMENT (“AGREEMENT”) is made on this 5th day of April, 2012, by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a member institution of SYSTEM, and SOLITON, INC. a Delaware corporation having a principal place of business located at 1225 N. Loop West, Suite 725, Houston, Texas 77008 (“LICENSEE”).
PATENT AND TECHNOLOGY LICENSE AGREEMENT Exh.10.2Patent and Technology License Agreement • May 14th, 2018 • Moleculin Biotech, Inc. • Pharmaceutical preparations • Texas
This AGREEMENT ("AGREEMENT") is made on this 12th day of February, 2018, by and between THE BOARD OF REGENTS ("BOARD") of THE UNIVERSITY OF TEXAS SYSTEM ("SYSTEM"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ("UTMDACC"), a member institution of SYSTEM, and Moleculin Biotech, Inc., a corporation organized and existing under the laws of the state of Delaware, having a principal place of business located at 2575 West Bellfort, Suite 333, Houston, Texas 77054 ("LICENSEE").
